WO2011012746A3 - Compuestos inhibidores de apaf-1 - Google Patents

Compuestos inhibidores de apaf-1 Download PDF

Info

Publication number
WO2011012746A3
WO2011012746A3 PCT/ES2010/000349 ES2010000349W WO2011012746A3 WO 2011012746 A3 WO2011012746 A3 WO 2011012746A3 ES 2010000349 W ES2010000349 W ES 2010000349W WO 2011012746 A3 WO2011012746 A3 WO 2011012746A3
Authority
WO
WIPO (PCT)
Prior art keywords
apaf
inhibitor compounds
piperazinedione
prophylaxis
apoptosis
Prior art date
Application number
PCT/ES2010/000349
Other languages
English (en)
French (fr)
Other versions
WO2011012746A2 (es
Inventor
Àngel MESSEGUER PEYPOCH
Alejandra MOURE FERNÁNDEZ
Daniel GONZÁLEZ PINACHO
Isabel Masip Masip
Enrique PEREZ PAYÁ
Natividad Garcia Villar
Ester MONLLEÓ MAS
Juanlo Catena Ruiz
Original Assignee
Laboratorios Salvat, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Salvat, S.A. filed Critical Laboratorios Salvat, S.A.
Priority to NZ598125A priority Critical patent/NZ598125A/en
Priority to JP2012522195A priority patent/JP5694320B2/ja
Priority to CA2769408A priority patent/CA2769408C/en
Priority to AU2010277505A priority patent/AU2010277505B2/en
Priority to IN1378DEN2012 priority patent/IN2012DN01378A/en
Priority to US13/387,240 priority patent/US9040701B2/en
Priority to ES10803937T priority patent/ES2727711T3/es
Priority to CN201080043254.1A priority patent/CN102574818B/zh
Priority to MX2012001339A priority patent/MX2012001339A/es
Priority to EA201270215A priority patent/EA021838B1/ru
Priority to BR112012002134A priority patent/BR112012002134B8/pt
Priority to KR1020127005131A priority patent/KR101786761B1/ko
Priority to EP10803937.1A priority patent/EP2460798B1/en
Publication of WO2011012746A2 publication Critical patent/WO2011012746A2/es
Publication of WO2011012746A3 publication Critical patent/WO2011012746A3/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Los derivados de 2,5-piperazinadiona de fórmula (I) son inhibidores del factor 1 activador de Ia peptidasa apoptótica (Apaf-1, Apoptotic Peptidase Activating Factor 1), por Io que resultan útiles como principios activos farmacéuticos para Ia profilaxis y/o tratamiento de una condición patológica y/o fisiológica asociada a un incremento de Ia apoptosis.
PCT/ES2010/000349 2009-07-30 2010-07-29 Compuestos inhibidores de apaf-1 WO2011012746A2 (es)

Priority Applications (13)

Application Number Priority Date Filing Date Title
NZ598125A NZ598125A (en) 2009-07-30 2010-07-29 Apaf-1 inhibitor compounds
JP2012522195A JP5694320B2 (ja) 2009-07-30 2010-07-29 Ａｐａｆ−１阻害剤化合物
CA2769408A CA2769408C (en) 2009-07-30 2010-07-29 Apaf-1 inhibitor compounds
AU2010277505A AU2010277505B2 (en) 2009-07-30 2010-07-29 APAF-1 inhibitor compounds
IN1378DEN2012 IN2012DN01378A (es) 2009-07-30 2010-07-29
US13/387,240 US9040701B2 (en) 2009-07-30 2010-07-29 Apaf-1 inhibitor compounds
ES10803937T ES2727711T3 (es) 2009-07-30 2010-07-29 Compuestos inhibidores de Apaf-1
CN201080043254.1A CN102574818B (zh) 2009-07-30 2010-07-29 Apaf-1抑制剂化合物
MX2012001339A MX2012001339A (es) 2009-07-30 2010-07-29 Compuestos inhibidores de apaf-1.
EA201270215A EA021838B1 (ru) 2009-07-30 2010-07-29 Производные 2,5-пиперазиндиона в качестве ингибиторов apaf-1
BR112012002134A BR112012002134B8 (pt) 2009-07-30 2010-07-29 compostos inibidores de apaf-1
KR1020127005131A KR101786761B1 (ko) 2009-07-30 2010-07-29 Ａｐａｆ-1 억제제 화합물
EP10803937.1A EP2460798B1 (en) 2009-07-30 2010-07-29 Apaf-1 inhibitor compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200901757 2009-07-30
ES200901757 2009-07-30

Publications (2)

Publication Number Publication Date
WO2011012746A2 WO2011012746A2 (es) 2011-02-03
WO2011012746A3 true WO2011012746A3 (es) 2011-07-14

Family

ID=43529761

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2010/000349 WO2011012746A2 (es) 2009-07-30 2010-07-29 Compuestos inhibidores de apaf-1

Country Status (15)

Country Link
US (1) US9040701B2 (es)
EP (1) EP2460798B1 (es)
JP (1) JP5694320B2 (es)
KR (1) KR101786761B1 (es)
CN (1) CN102574818B (es)
AU (1) AU2010277505B2 (es)
BR (1) BR112012002134B8 (es)
CA (1) CA2769408C (es)
EA (1) EA021838B1 (es)
ES (1) ES2727711T3 (es)
IN (1) IN2012DN01378A (es)
MX (1) MX2012001339A (es)
NZ (1) NZ598125A (es)
TR (1) TR201907804T4 (es)
WO (1) WO2011012746A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2476756A1 (en) 2005-06-15 2012-07-18 Massachusetts Institute of Technology Amine-containing lipids and uses thereof
CA3006395C (en) 2008-11-07 2022-05-31 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
ES2713852T3 (es) 2009-12-01 2019-05-24 Translate Bio Inc Derivado de esteroides para la administración de ARNm en enfermedades genéticas humanas
EP2609135A4 (en) 2010-08-26 2015-05-20 Massachusetts Inst Technology POLY (BETA-AMINO ALCOHOLS), THEIR PREPARATION AND USES THEREOF
WO2012135025A2 (en) 2011-03-28 2012-10-04 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
KR20200084048A (ko) 2011-06-08 2020-07-09 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
MX363734B (es) * 2011-10-27 2019-03-29 Massachusetts Inst Technology Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco.
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
EP2859102A4 (en) 2012-06-08 2016-05-11 Shire Human Genetic Therapies NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF
ES2443538B1 (es) * 2012-07-19 2014-11-26 Consejo Superior De Investigaciones Cientificas (Csic) Compuestos beta-lactámicos inhibidores de APAF1
EP2882706A1 (en) 2012-08-13 2015-06-17 Massachusetts Institute of Technology Amine-containing lipidoids and uses thereof
KR20210122917A (ko) 2013-03-14 2021-10-12 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna 조성물 및 관련 방법 및 사용
KR20150128687A (ko) 2013-03-14 2015-11-18 샤이어 휴먼 지네틱 테라피즈 인크. 메신저 rna의 정제 방법
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
MX2016005237A (es) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Terapia de acido ribonucleico mensajero para la deficiencia de argininosuccinato sintetasa.
EA201690576A1 (ru) 2013-10-22 2016-10-31 Шир Хьюман Дженетик Терапис, Инк. Липидные композиции для доставки матричной рнк
EA201992208A1 (ru) 2013-10-22 2020-07-31 Транслейт Био, Инк. ЛЕЧЕНИЕ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
WO2015164773A1 (en) 2014-04-25 2015-10-29 Shire Human Genetic Therapies, Inc. Methods for purification of messenger rna
CA2949106C (en) 2014-05-30 2023-10-24 Shire Human Genetic Therapies, Inc. Biodegradable lipids for delivery of nucleic acids
CN106795142B (zh) 2014-06-24 2022-11-04 川斯勒佰尔公司 用于递送核酸的立体化学富集组合物
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
CN113968823A (zh) 2015-06-19 2022-01-25 麻省理工学院 烯基取代的2,5-哌嗪二酮和其在组合物中用于向个体或细胞递送药剂的用途
EP3585417B1 (en) 2017-02-27 2023-02-22 Translate Bio, Inc. Method of making a codon-optimized cftr mrna
WO2018213476A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
US11273295B2 (en) 2018-04-19 2022-03-15 Spiral Therapeutics, Inc. Inner ear drug delivery devices and methods of use
CN112930396A (zh) 2018-08-24 2021-06-08 川斯勒佰尔公司 用于纯化信使rna的方法
US10561736B1 (en) 2019-01-09 2020-02-18 Spiral Therapeutics, Inc. Apoptosis inhibitor formulations for prevention of hearing loss
US20220126028A1 (en) 2019-02-25 2022-04-28 Spiral Therapeutics, Inc. Intratympanic injector devices and needles for delivery of drugs and methods of use
EP4137131A1 (en) * 2021-08-17 2023-02-22 Centre National de la Recherche Scientifique (CNRS) Novel serotonin analogues and their uses for treating iron-associated disorders
CN115124449B (zh) * 2022-05-24 2024-02-02 上海英诺富成生物科技有限公司 一种吲哚化合物及制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007060524A1 (en) * 2005-11-23 2007-05-31 Laboratorios Salvat, S.A. Compounds for the inhibition of apoptosis
WO2008009758A1 (es) * 2006-07-20 2008-01-24 Consejo Superior De Investigaciones Científicas Compuestos con actividad inhibidora de las interacciones ubc13-uev, composiciones farmacéuticas y aplicaciones terapéuticas

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560503A (en) * 1968-09-18 1971-02-02 Council Scient Ind Res Di-lower alkyl-substituted octahydropyrazinopyrimidinones
GB1284582A (en) * 1969-11-10 1972-08-09 Council Scient Ind Res Substituted piperazinopyrimidinones
JPH04234375A (ja) * 1990-12-27 1992-08-24 Ajinomoto Co Inc 新規２，５−ジオキソピペラジン化合物及びその製造法
WO1992019595A1 (en) * 1991-05-07 1992-11-12 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH05117246A (ja) * 1991-10-23 1993-05-14 Ajinomoto Co Inc 新規２，５−ジオキソピペラジン化合物とその製造法及びα−Ｌ−アスパルチル−Ｌ−フエニルアラニンメチルエステル誘導体の製造法
WO1996000391A1 (en) * 1994-06-23 1996-01-04 Affymax Technologies N.V. Methods for the synthesis of diketopiperazines
EP1351941B1 (en) * 2001-01-19 2004-09-29 Pharmacopeia, Inc. Bisaryl derivatives having fsh receptor modulatory activity
EP1571970B1 (en) 2002-10-02 2011-08-17 DMI Biosciences, Inc. Diagnosis and monitoring of diseases
WO2005052177A1 (ja) * 2003-11-28 2005-06-09 Kyowa Hakko Kogyo Co., Ltd. ジペプチドの製造法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007060524A1 (en) * 2005-11-23 2007-05-31 Laboratorios Salvat, S.A. Compounds for the inhibition of apoptosis
WO2008009758A1 (es) * 2006-07-20 2008-01-24 Consejo Superior De Investigaciones Científicas Compuestos con actividad inhibidora de las interacciones ubc13-uev, composiciones farmacéuticas y aplicaciones terapéuticas

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE BASE DE DATOS CAS; 17 February 2008 (2008-02-17), XP008151818, retrieved from STN Database accession no. 1003895-61-1 *
DATABASE BASE DE DATOS Database accession no. 1003895-53-1 *
DATABASE BASE DE DATOS Database accession no. 1003895-55-3 *
DATABASE BASE DE DATOS Database accession no. 1003895-57-5 *
G MALET ET AL.: "Small molecule inhibitors of Apaf-1-rtheated caspase-3/-9 activation that control mitochondrial dependent apoptosis", CELL DEATH AND DIFFERENTIATION, vol. 13, 2006, pages 1523 - 1532, XP008151304 *
See also references of EP2460798A4 *

Also Published As

Publication number Publication date
US20120122868A1 (en) 2012-05-17
IN2012DN01378A (es) 2015-06-05
EA201270215A1 (ru) 2012-11-30
CN102574818B (zh) 2015-02-25
ES2727711T3 (es) 2019-10-18
CA2769408C (en) 2017-09-05
CN102574818A (zh) 2012-07-11
WO2011012746A2 (es) 2011-02-03
TR201907804T4 (tr) 2019-06-21
BR112012002134A2 (pt) 2016-05-31
AU2010277505A1 (en) 2012-03-08
EP2460798A2 (en) 2012-06-06
EP2460798A4 (en) 2013-02-27
CA2769408A1 (en) 2011-02-03
KR20120052354A (ko) 2012-05-23
JP5694320B2 (ja) 2015-04-01
MX2012001339A (es) 2012-03-07
KR101786761B1 (ko) 2017-10-18
BR112012002134B8 (pt) 2021-05-25
JP2013500314A (ja) 2013-01-07
EP2460798B1 (en) 2019-02-27
AU2010277505B2 (en) 2016-01-14
NZ598125A (en) 2014-05-30
EA021838B1 (ru) 2015-09-30
US9040701B2 (en) 2015-05-26
BR112012002134B1 (pt) 2021-03-02

Similar Documents

Publication Publication Date Title
WO2011012746A3 (es) Compuestos inhibidores de apaf-1
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
MX2010006241A (es) Derivados de aminotriazol como agonistas de alx.
IN2012DN01233A (es)
UA106748C2 (uk) Похідні проліну як інгібітори катепсину
UA106037C2 (uk) Модулятори ampk (амф-активованої протеїнкінази)
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
PL2247602T3 (pl) Pochodne O-glukuronido-adamantylowe jako inhibitory dipeptydylopeptydazy IV do leczenia cukrzycy
PL2150530T3 (pl) Podstawione pochodne sulfonamidu
GEP20125650B (en) Thiophene or thiazole derivatives and use thereof as pi3k inhibitors
MX339759B (es) Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares.
WO2012046030A3 (en) Phosphodiesterase inhibitors
WO2010128050A3 (en) Dihydroorotate - dehydrogenasee inhibitors as virostatic compounds
NZ600874A (en) Fluorinated derivatives of deferiprone
TW200738651A (en) Cyclohexyl sulfonamide derivatives
IL199829A0 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
MX2012007582A (es) Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida.
WO2009074247A8 (de) Neue 2-aryl-thiazol-4-carbonsäureamid-derivate, deren herstellung und verwendung als arzneimittel
WO2009030952A3 (en) Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
WO2009082526A3 (en) Ortho pyrrolidine, benzyl-substituted heterocycle ccr1 antagonists for autoimmune diseases & inflammation
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
TN2012000242A1 (en) Heterocyclic sulfonamide derivatives
WO2011048011A3 (en) Benzotropolone derivatives as antimicrobial agents
WO2009074498A8 (en) Medical use of 3- (2, 2, 2-trimethylhydrazinixm) propionate orotate
WO2011000945A3 (en) Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080043254.1

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2769408

Country of ref document: CA

Ref document number: 13387240

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2012522195

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/001339

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2010277505

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1378/DELNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010803937

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20127005131

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201270215

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2010277505

Country of ref document: AU

Date of ref document: 20100729

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012002134

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012002134

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120130